Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Paratek Pharmaceuticals (PRTK) PT Lowered to $20 at Baird
November 7, 2018 9:04 AM ESTBaird analyst Michael Ulz lowered the price target on Paratek Pharmaceuticals (NASDAQ: PRTK) to $20.00 (from $30.00) while maintaining a Outperform rating.
The analyst commented, "Management reviewed the recent approval of Nuzyra (October) and reiterated a launch in February 2019, with pre-commercial activities on... More
